MX384453B - Métodos in vitro para identificar lactantes prematuros en riesgo de displasia broncopulmonar. - Google Patents

Métodos in vitro para identificar lactantes prematuros en riesgo de displasia broncopulmonar.

Info

Publication number
MX384453B
MX384453B MX2016016842A MX2016016842A MX384453B MX 384453 B MX384453 B MX 384453B MX 2016016842 A MX2016016842 A MX 2016016842A MX 2016016842 A MX2016016842 A MX 2016016842A MX 384453 B MX384453 B MX 384453B
Authority
MX
Mexico
Prior art keywords
risk
premature infants
bronchopulmonary dysplasia
methods
benefit
Prior art date
Application number
MX2016016842A
Other languages
English (en)
Other versions
MX2016016842A (es
Inventor
Douglas Stuart Greene
Jim Potenziano
Joseph J Medicis
Original Assignee
Mallinckrodt Hospital Products Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Hospital Products Ip Ltd filed Critical Mallinckrodt Hospital Products Ip Ltd
Publication of MX2016016842A publication Critical patent/MX2016016842A/es
Publication of MX384453B publication Critical patent/MX384453B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/497—Physical analysis of biological material of gaseous biological material, e.g. breath
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos para identificar lactantes prematuros en riesgo de desarrollar displasia broncopulmonar y/o con mayor probabilidad de beneficiarse de la administración de óxido nítrico inhalado para la prevención de la displasia broncopulmonar (BPD). Se proporcionan métodos para tratar lactantes prematuros identificados en riesgo y/o probablemente beneficiados. También se proporcionan métodos para identificar lactantes prematuros que no están en riesgo de desarrollar displasia broncopulmonar y/o poco probable que se beneficien de la administración de óxido nítrico inhalado para la prevención de la displasia broncopulmonar, y métodos para evitar riesgos de toxicidad y efectos secundarios indeseables asociados de la terapia con óxido nítrico inhalado que comprende administrar únicamente modalidades de tratamiento sin iNO a estos lactantes.
MX2016016842A 2014-06-20 2015-06-18 Métodos in vitro para identificar lactantes prematuros en riesgo de displasia broncopulmonar. MX384453B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014817P 2014-06-20 2014-06-20
PCT/US2015/036413 WO2015195903A1 (en) 2014-06-20 2015-06-18 Method of identifying and treating premature infants at risk for bpd

Publications (2)

Publication Number Publication Date
MX2016016842A MX2016016842A (es) 2017-05-08
MX384453B true MX384453B (es) 2025-03-14

Family

ID=53674258

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016842A MX384453B (es) 2014-06-20 2015-06-18 Métodos in vitro para identificar lactantes prematuros en riesgo de displasia broncopulmonar.

Country Status (5)

Country Link
US (3) US10613103B2 (es)
AU (1) AU2015277099A1 (es)
CA (1) CA2951933A1 (es)
MX (1) MX384453B (es)
WO (1) WO2015195903A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017384467B2 (en) * 2016-12-22 2023-10-19 Chiesi Farmaceutici S.P.A. A therapeutic combination comprising a pulmonary surfactant and a steroid for the treatment of evolving BPD
WO2020264239A1 (en) * 2019-06-27 2020-12-30 Uab Research Foundation Methods of diagnosing and predicting chronic lung and bowel disease in pre-term infants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120093948A1 (en) * 2009-11-20 2012-04-19 Fine David H Nitric Oxide Treatments
WO2013026902A1 (en) * 2011-08-23 2013-02-28 Aerocrine Ab Devices and methods for generating an artificial exhalation profile
WO2014210030A2 (en) 2013-06-25 2014-12-31 Ino Therapeutics Llc Methods of reducing the risk of mortality associated with a medical treatment

Also Published As

Publication number Publication date
AU2015277099A1 (en) 2017-01-05
US10613103B2 (en) 2020-04-07
US20200200773A1 (en) 2020-06-25
WO2015195903A1 (en) 2015-12-23
MX2016016842A (es) 2017-05-08
US12007399B2 (en) 2024-06-11
CA2951933A1 (en) 2015-12-23
US20170212133A1 (en) 2017-07-27
US20230003747A1 (en) 2023-01-05
US11474115B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX389560B (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
BR112015023910A2 (pt) terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX390363B (es) Combinacion de linagliptina y metformina
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2017015896A (es) Agente anticancerigeno.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
EP3134423A4 (en) 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
MX394541B (es) Dihidrotestosterona y derivados y promotores de dihidrotestosterona en el tratamiento del cancer
PH12018501790A1 (en) Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
EP4606387A3 (en) Methods of using interleukin-10 for treating diseases and disorders
MX384453B (es) Métodos in vitro para identificar lactantes prematuros en riesgo de displasia broncopulmonar.